 Psoriasis
"Psoriasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Descriptor ID |
D011565
|
| MeSH Number(s) |
C17.800.859.675
|
| Concept/Terms |
Pustulosis of Palms and Soles- Pustulosis of Palms and Soles
- Pustulosis Palmaris et Plantaris
- Palmoplantaris Pustulosis
- Pustular Psoriasis of Palms and Soles
|
Below are MeSH descriptors whose meaning is more general than "Psoriasis".
Below are MeSH descriptors whose meaning is more specific than "Psoriasis".
This graph shows the total number of publications written about "Psoriasis" by people in this website by year, and whether "Psoriasis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 1 | 1 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 3 | 1 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 0 | 3 | 3 | | 2009 | 3 | 1 | 4 | | 2010 | 0 | 1 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 2 | 0 | 2 | | 2013 | 2 | 1 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 6 | 1 | 7 | | 2016 | 4 | 1 | 5 | | 2017 | 5 | 1 | 6 | | 2018 | 7 | 0 | 7 | | 2019 | 3 | 1 | 4 | | 2020 | 2 | 0 | 2 | | 2021 | 6 | 2 | 8 | | 2022 | 1 | 0 | 1 | | 2023 | 7 | 0 | 7 | | 2024 | 2 | 3 | 5 | | 2025 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Psoriasis" by people in Profiles.
-
McMichael A, Shahriari M, Stein Gold L, Alkousakis T, Choi O, Bhutani T, Rodriguez AO, Tyring SK, Chan D, Rowland K, Albrecht L, Lynde C, Yadav G, Yeung J, Park-Wyllie L, Ma T, Jeyarajah J, Gao LL, Smith S, Moore AY, Vashi N, Kindred C, Grimes P, Desai SR, Taylor SC, Alexis A. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025 Sep 01; 161(9):912-922.
-
Alexis A, McMichael A, Soung J, Choi O, Alkousakis T, Alonso-Llamazares J, Shahriari M, Rodriguez AO, Bhutani T, Chan D, Rowland K, Sauder M, Hong HC, Yadav G, Yeung J, Jeyarajah J, Ma T, Gao LL, Park-Wyllie L, Green L, Lee M, Vashi N, Kindred C, Grimes P, Taylor SC, Desai SR. Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025 Sep 01; 161(9):901-911.
-
Alexis A, McMichael A, Vashi N, Bhutani T, Rodriguez AO, Yeung J, Choi O, Chan D, Alkousakis T, Bronner DN, Park-Wyllie L, Gao LL, Grimes P, Shahriari M, Yadav G, Kindred C, Taylor SC, Desai SR. Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement. JAMA Dermatol. 2025 Mar 01; 161(3):256-264.
-
Kantheti U, Forward TS, Lucas ED, Schafer JB, Tamburini PJ, Burchill MA, Tamburini BAJ. PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration. Sci Adv. 2025 Jan 31; 11(5):eadt3044.
-
Rafael Correia Rocha I, Finch MR, Ball JB, Harland ME, Clements M, Green-Fulgham S, Song G, Liu Y, Banov D, Watkins LR. An initial investigation of transcutaneous delivery of plasmid DNA encoding interleukin-10 for the treatment of psoriatic skin conditions. Brain Behav Immun. 2025 Jan; 123:903-913.
-
Day M, Heapy C, Norman P, Emerson LM, Murphy R, Hughes O, Thompson AR. Impact of childhood psoriasis on children and parents during transition to adolescence: An interpretative phenomenological analysis. Br J Health Psychol. 2025 Feb; 30(1):e12763.
-
Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, Merghoub T, Maier T, Bang A, Gu S, Salvador T, Moy AP, Lyubchenko T, Xiao O, Hall CF, Berdyshev E, Crooks J, Weight R, Kern JA, Leung DYM. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways. Clin Cancer Res. 2024 Jul 01; 30(13):2822-2834.
-
Brandling-Bennett HA, Arkin LM, Chiu YE, Hebert AA, Callen JP, Castelo-Soccio L, Co DO, Cordoro KM, Curran ML, Dalrymple AM, Flohr C, Gordon KB, Hanna D, Irvine AD, Kim S, Kirkorian AY, Lara-Corrales I, Lindstrom J, Paller AS, Reyes M, Begolka WS, Tom WL, Van Voorhees AS, Vleugels RA, Lee LW, Davies O, Siegfried EC. Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients. J Am Acad Dermatol. 2024 Jun; 90(6):1271-1275.
-
Wang LL, Tuohy S, Xu KL, Nace A, Yang R, Zheng Y, Burdick JA, Cotsarelis G. Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts. Adv Healthc Mater. 2024 05; 13(12):e2303256.
-
Silverberg JI, Boguniewicz M, Quintana FJ, Clark RA, Gross L, Hirano I, Tallman AM, Brown PM, Fredericks D, Rubenstein DS, McHale KA. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review. J Allergy Clin Immunol. 2024 Jul; 154(1):1-10.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|